Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

SRI International describes lipoxygenase inhibitors

July 20, 2021

Sumitomo Dainippon Pharma divulges 5-HT2A and/or 5-HT7 receptor antagonists

July 20, 2021

MUSK-targeting agonist antibody is protective against experimental congenital myasthenia

July 20, 2021

Scioto opens phase I study of SB-121 in participants with autistic disorder

July 19, 2021

ABBV-CLS-7262 studied in phase I for ALS

July 19, 2021

FDA accepts IND application for phase IIa study of Quilience as treatment of narcolepsy

July 19, 2021

ARKUDA Therapeutics describes new progranulin modulators

July 16, 2021

Adial reports preclinical data with adenosine analogues for pain

July 15, 2021

Revalesio initiates phase II study of RNS-60 in acute ischemic stroke

July 15, 2021

Oryzon cleared to begin phase IIb trial of vafidemstat in schizophrenia

July 14, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...